MedTrace Logo

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

NCT02960620 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-09-28

No results posted yet for this study

Summary

This is not a research study. The purpose is to provide supervised access to TheraSphere® therapy at this institution.

Conditions

Interventions

DEVICE

TheraSphere Treatment

TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.

Sponsors & Collaborators

  • Biocompatibles UK Ltd

    collaborator INDUSTRY

  • BTG International Inc.

    collaborator OTHER

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Junsung Choi, M.D. · H. Lee Moffitt Cancer Center and Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02960620 on ClinicalTrials.gov